Skip to main content
. 1999 Dec 15;104(12):1715–1722. doi: 10.1172/JCI8082

Figure 1.

Figure 1

Skin allograft rejection in B6 mice is relatively resistant to combined blockade of the CD40 and CD28 pathways. B6 recipients of Balb/c skin allografts treated with anti-CD40L (500 μg) and CTLA4-Ig (500 μg) on days 0, 2, 4, and 6 (MST 20 days; n = 7) had minimally prolonged survival compared with a control group that received no treatment (MST 10 days; n = 7; P < 0.01). Recipients treated with chronic costimulation blockade therapy (days 0, 2, 4, and 6 and weekly until rejection) (MST 17 days; n = 7) did not have prolonged survival compared with our standard CD40/CD28 blockade protocol.